Nanotop (Human Albumin Solution)

Human Albumin Solution, the active ingredient in Nanotop, is a plasma volume expander presented as a solution for injection for intradermal, intratumoral, and subcutaneous use. It increases plasma oncotic pressure and expands intravascular volume, helping to restore circulatory stability in patients with hypovolemia or hypoalbuminemia.

GNH USA supplies Nanotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The product meets EU quality standards and is available for bulk procurement to support critical care programs.

Human Albumin Solution is used as a plasma volume expander to manage conditions associated with low blood volume or albumin deficiency. - Hypovolemia (e.g., hemorrhage, trauma): restores circulating blood volume and improves hemodynamic stability. - Severe hypoalbuminemia (e.g., liver cirrhosis, nephrotic syndrome): raises serum albumin levels and enhances oncotic pressure. - Major burns: provides plasma protein replacement to support fluid resuscitation. - Cardiac surgery or major operative procedures: maintains intravascular volume during peri‑operative periods.

Human Albumin Solution may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever or chills: mild temperature elevation shortly after infusion. - Headache: transient discomfort during or after administration. - Nausea: mild gastrointestinal upset. - Hypotension: temporary drop in blood pressure. - Local irritation at injection site: redness or mild pain.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical intervention. - Volume overload: pulmonary edema in patients with compromised cardiac function. - Hemolysis: destruction of red blood cells leading to anemia. - Thromboembolic events: clot formation in veins or arteries. - Transmission of infectious agents: rare risk if product sterility is compromised.

When using Human Albumin Solution, clinicians should observe specific precautions to minimize risks and ensure optimal therapeutic benefit. - Indication assessment: verify that volume expansion or hypoalbuminemia correction is clinically indicated. - Cardiac status: evaluate for heart failure before administration to avoid volume overload. - Fluid balance monitoring: track input/output and weight to detect early signs of overload. - Allergic history: review patient’s prior reactions to albumin or blood products. - Concomitant diuretics: adjust dosing if patient is receiving diuretics that affect fluid status. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Albumin Solution can interact with other medicines, influencing fluid balance or immune response.

Major Interactions (Avoid): - Diuretics (e.g., furosemide): may exacerbate hypovolemia if albumin is not administered concurrently. - ACE inhibitors or ARBs: increased risk of hypotension when combined with rapid volume expansion. - Anticoagulants (e.g., heparin): potential for altered plasma protein binding affecting drug activity. - Corticosteroids: may mask signs of fluid overload, requiring closer observation.

Moderate Interactions (Monitor Closely): - Vasopressors: dose adjustments may be needed as albumin changes intravascular volume. - Immunoglobulins: concurrent infusion may increase risk of renal dysfunction. - Chemotherapeutic agents: monitor for changes in drug distribution due to altered plasma proteins. - Beta‑blockers: may blunt compensatory tachycardia during volume expansion.